Cargando…
Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia
Resistance to regulated cell death is one of the hallmarks of human cancers; it maintains cell survival and significantly limits the effectiveness of conventional drug therapy. Leukemia represents a class of hematologic malignancies that is characterized by dysregulation of cell death pathways and t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291981/ https://www.ncbi.nlm.nih.gov/pubmed/30541583 http://dx.doi.org/10.1186/s13046-018-0976-z |
_version_ | 1783380320557465600 |
---|---|
author | Huang, Xianbo Xiao, Feng Li, Yuan Qian, Wenbin Ding, Wei Ye, Xiujin |
author_facet | Huang, Xianbo Xiao, Feng Li, Yuan Qian, Wenbin Ding, Wei Ye, Xiujin |
author_sort | Huang, Xianbo |
collection | PubMed |
description | Resistance to regulated cell death is one of the hallmarks of human cancers; it maintains cell survival and significantly limits the effectiveness of conventional drug therapy. Leukemia represents a class of hematologic malignancies that is characterized by dysregulation of cell death pathways and treatment-related resistance. As the majority of chemotherapeutic and targeted drugs kill leukemia cells by triggering apoptosis, the observed resistance indicates the need for novel therapeutic strategies to reactivate nonapoptotic cell death programs in refractory leukemia. Necroptosis is a regulated form of necrosis that is precisely modulated by intracellular signaling pathways and thus provides potential molecular targets for rational therapeutic intervention. Indeed, accumulating evidence indicates that many current antitumor agents can activate necroptotic pathways and thereby induce leukemia cell death. Elucidation of the complete regulatory mechanism of necroptosis is expected to accelerate the development of novel therapeutic strategies for overcoming apoptosis resistance in leukemia. Here, we review the latest research advances in the regulatory mechanisms of necroptosis and summarize the progression of necroptosis-based therapeutic strategies in leukemia. |
format | Online Article Text |
id | pubmed-6291981 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62919812018-12-17 Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia Huang, Xianbo Xiao, Feng Li, Yuan Qian, Wenbin Ding, Wei Ye, Xiujin J Exp Clin Cancer Res Review Resistance to regulated cell death is one of the hallmarks of human cancers; it maintains cell survival and significantly limits the effectiveness of conventional drug therapy. Leukemia represents a class of hematologic malignancies that is characterized by dysregulation of cell death pathways and treatment-related resistance. As the majority of chemotherapeutic and targeted drugs kill leukemia cells by triggering apoptosis, the observed resistance indicates the need for novel therapeutic strategies to reactivate nonapoptotic cell death programs in refractory leukemia. Necroptosis is a regulated form of necrosis that is precisely modulated by intracellular signaling pathways and thus provides potential molecular targets for rational therapeutic intervention. Indeed, accumulating evidence indicates that many current antitumor agents can activate necroptotic pathways and thereby induce leukemia cell death. Elucidation of the complete regulatory mechanism of necroptosis is expected to accelerate the development of novel therapeutic strategies for overcoming apoptosis resistance in leukemia. Here, we review the latest research advances in the regulatory mechanisms of necroptosis and summarize the progression of necroptosis-based therapeutic strategies in leukemia. BioMed Central 2018-12-12 /pmc/articles/PMC6291981/ /pubmed/30541583 http://dx.doi.org/10.1186/s13046-018-0976-z Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Huang, Xianbo Xiao, Feng Li, Yuan Qian, Wenbin Ding, Wei Ye, Xiujin Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia |
title | Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia |
title_full | Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia |
title_fullStr | Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia |
title_full_unstemmed | Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia |
title_short | Bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia |
title_sort | bypassing drug resistance by triggering necroptosis: recent advances in mechanisms and its therapeutic exploitation in leukemia |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291981/ https://www.ncbi.nlm.nih.gov/pubmed/30541583 http://dx.doi.org/10.1186/s13046-018-0976-z |
work_keys_str_mv | AT huangxianbo bypassingdrugresistancebytriggeringnecroptosisrecentadvancesinmechanismsanditstherapeuticexploitationinleukemia AT xiaofeng bypassingdrugresistancebytriggeringnecroptosisrecentadvancesinmechanismsanditstherapeuticexploitationinleukemia AT liyuan bypassingdrugresistancebytriggeringnecroptosisrecentadvancesinmechanismsanditstherapeuticexploitationinleukemia AT qianwenbin bypassingdrugresistancebytriggeringnecroptosisrecentadvancesinmechanismsanditstherapeuticexploitationinleukemia AT dingwei bypassingdrugresistancebytriggeringnecroptosisrecentadvancesinmechanismsanditstherapeuticexploitationinleukemia AT yexiujin bypassingdrugresistancebytriggeringnecroptosisrecentadvancesinmechanismsanditstherapeuticexploitationinleukemia |